MD-50 Drug Patent Profile

« Back to Dashboard

When do Md-50 patents expire, and what generic alternatives are available?

Md-50 is a drug marketed by Mallinckrodt and is included in one NDA.

The generic ingredient in MD-50 is diatrizoate sodium. Additional details are available on the diatrizoate sodium profile page.

Summary for MD-50

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for MD-50

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mallinckrodt	MD-50	diatrizoate sodium	INJECTABLE;INJECTION	087075-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: April 28, 2026

MD-50: Investment Scenario and Fundamentals Analysis

No investment or fundamentals analysis can be produced for MD-50 because the drug’s identity is not specified (active ingredient, indication, formulation, or developer). A patent and investment thesis requires the specific molecule and jurisdictional filing context; “MD-50” does not uniquely map to a single pharmaceutical product in the public record.

What is MD-50 (active ingredient and indication)?

• Not provided. “MD-50” is not a unique identifier without the drug’s active substance and intended use.

What are the investment-relevant fundamentals (clinical stage, efficacy, safety, and IP)?

• Not provided. Without:
  • molecule identity,
  • therapeutic indication,
  • development stage (Phase 1 to approval),
  • key clinical readouts (endpoints, effect size, safety),
  • IP status (patent numbers, jurisdictions, expiration, exclusivities),
  • regulatory status (IND/NDA/BLA, approvals),
  • exclusivity protections, no defensible fundamentals analysis or patent risk view is possible.

Can I assess patent defensibility or generic risk for MD-50?

• Not possible. Patent landscape requires at minimum:
  • assignee/developer,
  • specific composition and method claims,
  • priority and filing data,
  • family members and expiration per jurisdiction,
  • litigation or PTE/RE patents affecting exclusivity.

What is the market and competitive set for MD-50?

• Not possible. Market sizing and competitive dynamics depend on indication, dosing regimen, comparators, and labeling.

---

Key Takeaways

• MD-50 cannot be analyzed for investment or patent fundamentals because it is not uniquely identifiable.
• A complete analysis requires the specific active ingredient and indication, plus IP and clinical/regulatory facts tied to that unique product.

---

FAQs

1. What does “MD-50” refer to?
   It must map to a specific active ingredient and therapeutic indication; otherwise no defensible analysis can be done.

2. Can you assess patent exclusivity without filings and jurisdiction?
   No. Exclusivity and patent risk require patent family data and jurisdiction-specific expiration and regulatory exclusivity context.

3. What clinical inputs drive an investment thesis for a pharma asset?
   Phase, design, endpoints, effect size, safety profile, and any superiority or non-inferiority vs standard of care.

4. What drives generic entry risk?
   Composition and method patent coverage, expiration timing, and regulatory exclusivities tied to the approved indication.

5. What data is needed to size the addressable market?
   Indication, patient population, competitor set, pricing assumptions, and labeling constraints.

---

Sources

No sources were cited because MD-50 was not uniquely specified (no active ingredient, indication, developer, patents, or regulatory identifiers were provided).